If you’ve ever run a clean experiment on paper but ended up with messy, confusing results, you’re not alone. One of the most common frustrations researchers face is unexpected bands or signals caused by polyclonal antibody binding to off-target proteins. It’s especially tricky because polyclonal antibodies are widely used for their sensitivity, yet that same strength can quickly turn into a drawback. [Read more…]
Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial
Melbourne, Australia; 8 April 2024 – Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU). [Read more…]
Aruna Bio Announces FDA Clearance of IND for Lead Program AB126, Enabling the First Exosome to Enter in Human Clinical Trials for a Neurological Indication
-Phase 1b/2a clinical trial in acute ischemic stroke expected to initiate in 1H 2024-
-Marks the first IND for Aruna’s platform with plans to expand AB126, an unmodified exosome derived from proprietary neural stem cells, to other neurological indications including amyotrophic lateral sclerosis-
-Proprietary in-house GMP production capabilities enable scalable, reproducible production of clinical-grade exosomes with high purity and uniformity; analytical methods and well-characterized assays established to ensure therapeutic consistency-
Regenerative Applications Of Placental Tissue Allografts With Dr. Bruce Werber
I had the privilege of speaking with Dr. Bruce Werber about the innovative use of placental tissue allografts in regenerative medicine. With 35 years of experience as a board-certified foot and ankle surgeon, Dr. Werber also serves as the COO of BioTech Products, Services, and Research (BPSR) and the CEO of its subsidiary, Anu Life Sciences.
Cryo-Cell to Spin-off Celle Corp., Its Subsidiary Holding Assets Not Directly Associated with Recurring Revenue from Biopreservation
Celle Corp. holds certain assets of Cryo-Cell not directly associated with its recurring revenue derived from privately banked cord blood specimens.
OLDSMAR, Fla.–Cryo-Cell International, Inc. (NYSE American LLC: CCEL), the world’s first private cord blood bank to separate and store stem cells in 1992, announced that its Board of Directors has authorized the spin-off of its newly formed subsidiary, Celle Corp., to the Cryo-Cell shareholders and to explore all strategic alternatives for Cryo-Cell (post spin-off) to maximize shareholder value, including, but not limited to, equity and/or debt financings and/or the possible sale or merger of the company. There is no assurance that such a transaction will take place. [Read more…]
- « Previous Page
- 1
- …
- 102
- 103
- 104
- 105
- 106
- …
- 338
- Next Page »